CN104585767A - Health product with function of reducing blood fat and preparation process of health product - Google Patents
Health product with function of reducing blood fat and preparation process of health product Download PDFInfo
- Publication number
- CN104585767A CN104585767A CN201510063794.0A CN201510063794A CN104585767A CN 104585767 A CN104585767 A CN 104585767A CN 201510063794 A CN201510063794 A CN 201510063794A CN 104585767 A CN104585767 A CN 104585767A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- health products
- blood
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 title claims abstract description 50
- 230000036541 health Effects 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 21
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 21
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 20
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 20
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 20
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 50
- 235000013305 food Nutrition 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 238000004040 coloring Methods 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 241000218628 Ginkgo Species 0.000 claims description 19
- 238000005516 engineering process Methods 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 244000028550 Auricularia auricula Species 0.000 claims description 6
- 235000000023 Auricularia auricula Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 240000001008 Dimocarpus longan Species 0.000 claims description 5
- 235000000235 Euphoria longan Nutrition 0.000 claims description 5
- 244000241838 Lycium barbarum Species 0.000 claims description 5
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 18
- 210000000952 spleen Anatomy 0.000 abstract description 17
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 210000001367 artery Anatomy 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000003462 vein Anatomy 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 235000007189 Oryza longistaminata Nutrition 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004087 circulation Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000005195 poor health Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 231100000216 vascular lesion Toxicity 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 230000002402 anti-lipaemic effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- QDGIAPPCJRFVEK-UHFFFAOYSA-N (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate Chemical compound C1CN(C)CCC1OC(=O)C(OC=1C=CC(Cl)=CC=1)OC1=CC=C(Cl)C=C1 QDGIAPPCJRFVEK-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229950009619 lifibrate Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a health product with a function of reducing blood fat and a preparation process of the health product. The health product provided by the invention can be used for treating the cardiovascular disease. The health product provided by the invention takes three aspects of relieving vasospasm, dissolving thrombus and removing fat, and repairing damaged blood vessels into account, and can be used for radically solving vasculopathy causing the cardia-cerebrovascular disease by using effects of stabilizing collaterals and activating arteries and veins, removing stasis and dispelling dampness, invigorating circulation of blood, and promoting fresh blood production. The health product is prepared from the raw materials of red rice, pseudo-ginseng, folium apocyni veneti, folium ginkgo and kudzuvine roots which are matched, and has effects of invigorating spleen to eliminate dampness, promoting blood circulation to remove blood stasis, removing heat from the liver, and tonifying the spleen and harmonizing the liver aiming at pathogenesis of poor health caused by insufficiency of the spleen, heat caused by liver depression, blood stasis caused by qi stagnation, and disharmony of the spleen and the liver in hyperlipidemia, so as to achieve a health function of assisting on reducing the blood fat. Meanwhile, the health product can achieve effects of repairing the blood vessels and reducing the morbidity of the cardiovascular disease while the blood fat is reduced.
Description
Technical field
The present invention relates to traditional Chinese medicine health care product, in particular to a kind of health products and the preparation technology that reduce blood fat.
Background technology
Hyperlipidemia is because fat metabolism or running make a kind of illness that cholesterol, triglycerides and (or) low-density lipoprotein are too high and (or) HDL is too low and cause extremely.The early stage majority of hyperlipidemia does not have clinical manifestation, to the infringement of health be concealment, gradually, Progressive symmetric erythrokeratodermia and general.Systemic atherosclerosis is strengthened in its direct infringement, and the vitals of whole body rely on artery blood supply, oxygen supply, once atheromatous plaque blocking artery, will cause serious consequence.Large quantity research shows, the atherosclerotic that hyperlipidemia causes causes the main cause of coronary heart disease, hypertension and cranial vascular disease, is also the hazards promoting diabetes, also can causes the generation of the disease such as fatty liver, cirrhosis.
Current Western medicine lipid lowerers mainly contains two large classes, to reduce T-CHOL and low-density lipoprotein for main first-elected Statins, comprises Lovastatin, Simvastatin, Pravastatin etc.; Reducing triglycerides is main person with the special class of shellfish for representative, as fenofibrate, and Lifibrate, ciprofibrate and Clofibrate etc.But they have very serious side effect: as stomachache, diarrhoea, abdominal distension, feels sick, and transaminase raises, nasal obstruction, headache, pharyngalgia, influenza syndrome, nasosinusitis, pectoralgia, insomnia, apocleisis, and hepatic and renal function is abnormal, myalgia etc.The effect for reducing fat of Western medicine is by blocking Fatty synthesis, or reduce fat to reach.Create a large amount of in this process, more harmful than fat, more difficult decomposition, the human toxin of more difficult excretion is really lose more than gain.More importantly, Western medicine reducing blood lipid is inreal solves human body production hyperliposis, utilizes the real cause of disease that fat is not enough, causes some patient to take medicine all the life, stand the hardship of huge side effect murder by poisoning all the life; Which kind of lipid lowerers no matter some patient use, and blood fat all can fall, and after some patient's medication, blood fat does not fall and soars on the contrary.Therefore, adopt Western medicine to reduce blood fat and can bring many harm and side effect to the person.
And in actual life, hypertension and high fat of blood exist often together.The harm of high blood pressure burst is high mortality, high disability rate.After high blood pressure develops into certain phase, easily occur " sudden heart stalk and sudden apoplexy (cerebral infarction or cerebral hemorrhage) ".Heart stalk, apoplexy, as rescued not in time, all can cause death.Even if apoplexy is rescued in time, also apoplexy sequelae can must be fallen in various degree.
The vascular lesion of diabetes is one of common diabetic complications, and this is also cause one of diabetic main causes of death, and modal vascular lesion has cardiovascular pathological changes, cerebrovascular disease, the microangiopathies etc. of kidney, retina and skin.The vascular complication that the vascular complication that heart disease, apoplexy sequelae, high blood pressure cause, diabetes cause, the co-morbid reason of these diseases is exactly vascular lesion.The cardiovascular and cerebrovascular diseases caused by vascular lesion, have become and have had a strong impact on human health, one of most dangerous diseases causing high mortality, high disability rate
Therefore, market needs one have no side effect, can effectively reduce human body blood fat and the health products of Cardiovarscular or medicine.
Summary of the invention
Consultant's YAN Zheng-hua professor that applicant company is engaged thinks: the vascular lesion causing cardiovascular and cerebrovascular diseases, and mainly from two aspects, " one is the spasm of blood vessel own; Two is that internal blood vessel has blood lipid deposition ", the two affects each other, and the result caused is exactly that " blood vessel elasticity goes down, and sclerosis increases the weight of; Vascular wall is impaired to be increased the weight of, thinning; Intravascular Thrombus is formed ".
So when blood vessel elasticity is not enough, when vascular wall is thinning, just easily cause rupture of blood vessel in brain, we are referred to as cerebral hemorrhage and hemorrhagic cerebral apoplexy; And when blood vessel elasticity is not enough, when thrombus is progressively formed, cerebral infarction or heart stalk can be caused again.
Vascular lipid deposits, on the one hand by the impact of high fat of blood, also relevant with vasopasm on the other hand; Vasopasm, the impacts such as mainly caused by the excitement of cerebral cortex layer, the excitement of cerebral cortex layer is stressed again, mood.So job and life stress is large, love is angry, mood is smooth, it is excited more easily to produce cerebral cortex layer to higher, the eager to do well in everything perfectionist of oneself requirement; Eat very goodly grow very much greasy, the few people's blood fat of activity is just easily high.Certainly, also the most easily there are cardiovascular and cerebrovascular diseases in this two classes crowd.
A lot of cardiovascular and cerebrovascular patient now, why control bad for a long time, or do not catch in treatment and cause the basic of vascular lesion, as the medicine taken, be the expander (to remove vasopasm be two different concepts to direct hemangiectasis from by nursing one's health cerebral cortex layer) directly acting on blood vessel, or be lipid lowering agent or blood-activating formula.
So a lot of cardiovascular and cerebrovascular patient, has three kinds of general situations: one is that blood fat has lowered by taking lipid lowerers, but cardiovascular and cerebrovascular diseases also exist; Two is that blood fat is not high, within normal range (NR), but has cardiovascular and cerebrovascular diseases; Three is that taken in a large number can the medicine of direct hemangiectasis, but effect worse and worse, even arrives and finally create secondary failure.
Therefore, for the problems referred to above, the present invention uses for reference the rules for the treatment of of Traditional Chinese Medicine theory to hyperlipemia, again in conjunction with modern pharmacology experimental study, select red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine to be primary raw material, have developed the joyful capsule of square board in health food side through the processing of modern crafts science.The present invention with red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine for primary raw material, mutual compatibility between each raw material, without incompatibility, formula and consumption all can play the health care of significant auxiliary antilipemic, and fundamentally can solve the crux of cardiovascular disease.
Below the scientific rationality of this product screening raw material is set forth respectively from the mechanism of action of red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine and efficacy effect and compatibility relationship.Red colouring agent for food, also used as a Chinese medicine taste is sweet, warm in nature, returns liver, spleen, large intestine channel, has invigorating the spleen for eliminating dampness, effect promoting blood circulation and removing blood stasis.Pseudo-ginseng is sweet, micro-hardship, temperature.Return liver, stomach warp.Its main function is to invigorate blood circulation, promote blood circulation the row stasis of blood.Folium Apocyni Veneti is cool in nature, and taste is sweet, bitter, returns Liver Channel.Having clearing liver fire, calming the liver to stop the wind effect, is the Chinese medicine of traditional calming liver and clearing heat simply.Ginkgo leaf taste is sweet, bitter, puckery, and property is put down, the thoughts of returning home, lung channel, the traditional Chinese medical science think its have promoting blood circulation and removing blood stasis, change turbid lipopenicillinase, the effect such as to astringe the lung.Root of kudzu vine taste is sweet, pungent, cool in nature, returns spleen, stomach warp.Motherland's medical science thinks that the root of kudzu vine rises sun, promotes the production of body fluid, invigorates blood circulation, dredging collateral, and proposes Bu Jinfa and invigorating the spleen to rise.Each material combination above, hyperlipemia of hitting is insufficiency of the spleen and lose strong fortune, liver depression knot and hot, the interpretation of the cause, onset and process of an illness that qi depression to blood stasis, spleen liver are uncomfortable, plays effect of invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing liver, tonifying spleen and liver altogether, reaches the health care of auxiliary antilipemic.A large amount of modern pharmacological research also in the side of proof each raw material all there is significant effect for reducing blood fat, and the present invention fundamentally solves the cause of disease of cardiovascular disease, may be used for treating the cardiovascular disease of heart disease crowd, hypertension and vascular complication crowd, apoplexy sequelae crowd, diabetes and vascular complication crowd, people with hyperlipidemia.(in the present invention used be originally conventional commercial Chinese medicine)
Specifically, on the one hand, the invention provides a kind of preparation technology reducing the health products of blood fat, it is characterized in that, it comprises the steps:
1) pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part is prepared, respectively, by weight;
2), by step 1) in the Chinese medicine for preparing add in extractor, and add ethanolic solution in described extractor;
3), in described extractor, carried out to prepared Chinese medicine the alcohol extracting scheduled time;
4), to the mixture in described extractor filter, discard the dregs of a decoction, obtain alcohol extract;
5), to described alcohol extract carry out reduced pressure concentration and obtain corresponding thick medicinal extract, and reclaim ethanol;
6), to described thick medicinal extract carry out drying, obtain dry extract;
7), by described dry extract pulverize and sieve, obtaining extract extract powder;
8), prepare red colouring agent for food, also used as a Chinese medicine 85-170 part, and radiation sterilizing is carried out to prepared red colouring agent for food, also used as a Chinese medicine;
9), by the red colouring agent for food, also used as a Chinese medicine through sterilization processing pulverize, obtain red colouring agent for food, also used as a Chinese medicine powder;
10), by described red colouring agent for food, also used as a Chinese medicine powder mix with described extract extract powder, obtain the medicinal powder of described health product;
11), quantitative separating is carried out to described medicinal powder.
In the present invention, dry run preferably adopts vacuum drying mode, certainly, does not get rid of and also can adopt other drying modes.Water used herein can, for meeting the drinking water of national standard, also can be purified water.
Further, described preparation technology is also included in described dry extract and adds starch 8-25 part and dolomol 1.8-3.5 part.
Further, the consumption of described red colouring agent for food, also used as a Chinese medicine be 135 parts, pseudo-ginseng 250 parts, Folium Apocyni Veneti 200 parts, ginkgo leaf 750 parts, the root of kudzu vine 750 parts.
Further, described red colouring agent for food, also used as a Chinese medicine warp
60co radiation sterilizing, and when carrying out concentrated to alcohol extract, the concentrated condition adopted is: temperature 55 ~ 65 DEG C, vacuum 0.08MPa; And described alcohol extract being concentrated into relative density is 1.20 ~ 1.25.
Further, described mixture is enclosed in capsule by described also comprising, and every capsules adds medicinal powder described in 0.4-0.5g.
On the other hand, the invention provides a kind of health products reducing blood fat, it is characterized in that, pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part is comprised in described health products, or the extract of pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part, and in described health products, comprise red colouring agent for food, also used as a Chinese medicine 85-170 part.
Further, described health products comprise pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, formed the after drying powder of dry extract of alcohol extract of the root of kudzu vine and the powder of red colouring agent for food, also used as a Chinese medicine.
Further, the consumption of each raw material is 135 parts, red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng 250 parts, Folium Apocyni Veneti 200 parts, ginkgo leaf 750 parts, the root of kudzu vine 750 parts by mass.
Further, the water extract powder of auricularia auriculajudae, longan and matrimony vine is also comprised in described health products.
On the other hand, the invention provides a kind of application of described health products, it is characterized in that, described health products are applied to Cardiovarscular.
It should be noted that, although the present invention is the theme with health products to be described the content of this patent application, but those skilled in the art should understand that, health products mentioned herein both can refer to the product for health care said in ordinary meaning, and can refer to Chinese herbal product or medicine.
In addition, formula of the present invention and improvement formula on this basis, by follow-up with side in the name of Fang Xinxin capsule put on market, any use to this formula all needs the permission obtaining Beijing Fang Zhongfang Science and Technology Ltd..
In addition, it should be noted that, although define the quality of each raw material in claims, it should be appreciated by those skilled in the art that the composition of each raw material equal proportion can increase or reduce.
The effect of health products of the present invention:
The present invention selects red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine as raw material, each material combination, hyperlipemia of hitting is insufficiency of the spleen and lose strong fortune, liver depression knot and hot, the interpretation of the cause, onset and process of an illness that qi depression to blood stasis, spleen liver are uncomfortable, play effect of invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing liver, tonifying spleen and liver altogether, reach the health care of auxiliary antilipemic.
Three aspects that product of the present invention is taken into account " remove vasopasm, thrombolysis row fat, repair damaged blood vessels ", synchronously set about, are main idea, fundamentally can solve the vascular lesion causing cardiovascular and cerebrovascular diseases with " steady network arteries and veins alive, row is turbid for the stasis of blood of dispelling, removing phlegm to promote blood circulation ".
Accompanying drawing explanation
Fig. 1 is the preparation flow schematic diagram of health products according to an embodiment of the invention.
Detailed description of the invention
Embodiment one
In the present embodiment, preparation adopt raw material as follows:
Table 1
Before medicine preparation, first need to clean above-mentioned material, sterilization etc.Choosing of each material all meets relevant national standard.
Prepared by medicinal powder
1, the alcohol extracting of pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine
By in table 1 with measuring pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine, clean, be placed in positive cone extractor, 70% ethanol then adding 8 times amount extracts, and extracts 2 hours, the active principle in above-mentioned material is dissolved in solution.Then, gained mixture is filtered, obtain first alcohol extract.In the medicinal material filtering gained, again add 70% ethanolic solution of 8 times amount, filtration is carried out to gained mixture and obtains second batch alcohol extract.
Mixed by the alcohol extract of twice acquisition and be placed in vacuum concentration pot, being evaporated to relative density is 1.20 ~ 1.25 (60 DEG C of mensuration) (concentrated condition: 55 ~ 65 DEG C, 0.08Mpa), obtains corresponding thick medicinal extract.Vacuum drying (technological parameter: temperature is 70 ~ 80 DEG C, vacuum is 0.08Mpa) is carried out to the thick medicinal extract of gained, obtains dry extract.Then dry extract is pulverized, cross 80 mesh sieves, obtain extract extract powder.
Next, get red colouring agent for food, also used as a Chinese medicine 135g, red colouring agent for food, also used as a Chinese medicine is carried out
60co irradiation (5KGy) sterilization processing.Red colouring agent for food, also used as a Chinese medicine after sterilization processing is pulverized, red colouring agent for food, also used as a Chinese medicine powder is crossed 80 mesh sieves, obtain Hongqu powder (red colouring agent).
Then, by extract extract powder and Hongqu powder (red colouring agent) mixing, add starch 30g and dolomol 3g, be then placed in movement mixer, mix 30 minutes.Until mixed powder color and luster is consistent, no color differnece, obtains mixed powder after mixing.Take out mixed powder, be filled in capsule, in each capsules, add the medicinal powder of 0.45g.Capsule is bottled, every bottle of 60 capsules.Then, encapsulate the medicine bottle installing capsule, form product, after quality testing is qualified, warehouse-in stores.
Validity check
In order to verify the effect of Chinese herbal product prepared in the present embodiment, applicant utilizes SD rat to carry out zoopery.
Specifically, first, prepare 200 male rats, feed with high lipid food respectively, feeding environment is selected in temperature 20-25 degree, humidity 40-70%RH.After nursing two weeks, from these 200 rats, select body weight 150-180g, serum total cholesterol content at more than 2.2mmol/L, serum triglyceride content is at the male rat 60 of more than 1.8mmol/L.These 60 rats are divided into two groups, often organize 30, ensure the mean cholesterol content of two groups of rats and average triglyceride content substantially equal.
Two groups of rats respectively as tested group and control group, then respectively to the high lipid food of two groups of feeding rats 1/3 and the chow diet of 2/3.Just for the rat in tested group, additionally give the medicinal powder of the present invention of 0.1g every day, after adhering to feeding two weeks, blood drawing checks serum triglyceride and the cholesterol level of two groups of rats again.
Can be found by zoopery above, product of the present invention obviously can reduce the content of triglycerides and cholesterol in animal body.
In addition, after having carried out zoopery, applicant of the present invention, before its product of release, has also carried out clinical trial to a large amount of cardiovascular patient.
Product of the present invention has effect of vascular repair, thrombolysis lipid-lowering, row's bolt row fat.But, due to when clinical trial, for the impact not easily quantitative evaluation of the vascular repair of patient after taking medicine, thrombolysis lipid-lowering, row's bolt row fat aspect, the clinical trial of product of the present invention is mainly tested from the reduction of the reduction of patients with lipid, blood pressure and patient's readme body-feeling aspect.
Specifically, after have chosen 50 hypertension and vascular complication patient, the blood pressure of these patients, blood fat are measured, and record patient is to the description of self symptom.Then, after appointing secret and liability clause, according to dosage take product of the present invention to these 50 patients.When taking two weeks and one month, Measure blood pressure, blood fat again, and record patient is to the description of self-condition.By the measurement to patients' blood and blood fat, find that the blood pressure of patient and blood fat all have obvious reduction, blood pressure and blood fat value can close to the upper limits of normal value afterwards taking one month for most of patient, and part can get back to normal value.And according to the description of patient, the symptom of its each side also has obvious alleviation.Such as, have the patient of numbness in hands and feet, mostly after taking a period of time, symptom will obviously be alleviated.
Embodiment two
In the present embodiment, adopt and preparation method similar in embodiment one, just have adjusted the proportioning of raw material.In the present embodiment, the pulp furnish adopted is as follows:
Table 3
Adopt and method substantially identical in embodiment one, applicant prepares corresponding medicinal powder based on the pulp furnish in table 3.
Similarly, for the product that this formula is produced, applicant also tests, and experimental technique is substantially identical.The experiment proved that, the product of this dose ratio, even than the dose ratio better effects if of embodiment one.
Embodiment three
In the present embodiment, carried out improving further to embodiment two, in the present embodiment, pulp furnish is as follows:
Table 4
In the present embodiment, still carry out product preparation according to the step shown in Fig. 1, just before medicine mixing, add the water extract of auricularia auriculajudae, longan, white fungus, matrimony vine.The water extraction of auricularia auriculajudae, longan, white fungus, matrimony vine adopts the water temperature of 80-100 degree Celsius, extracts at twice, and then the product after extraction is dry, pulverizing, is mixed in medicinal powder, Homogeneous phase mixing.
The present embodiment adds the extract of food composition in formula, and cost is cheaper, health environment-friendly, and, containing Auricularia polysaccharide in auricularia auriculajudae, there is the effect reducing blood fat.Adopt water extraction can obtain its active ingredient better.Auricularia auriculajudae, longan, white fungus, matrimony vine and the five kinds of Chinese medicine added before cooperate gentleer, better to the repairing effect of blood vessel, also can take for deficiency-cold in spleen and stomach patient.
It should be noted that; although with specific embodiments and the drawings describes in detail invention has been above; but; description is above only schematically illustrate; so that those skilled in the art's the understanding of the present invention, the restriction of detail not to invention protection domain of parts shown in figure.Those skilled in the art also should be appreciated that, above-described embodiment is also only the explanation to exemplary implementation of the present invention, not limiting the scope of the invention.
Claims (10)
1. reduce a preparation technology for the health products of blood fat, it is characterized in that, it comprises the steps:
1) pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part is prepared, respectively, by weight;
2), by step 1) in the Chinese medicine for preparing add in extractor, and add ethanolic solution in described extractor;
3), in described extractor, carried out to prepared Chinese medicine the alcohol extracting scheduled time;
4), to the mixture in described extractor filter, discard the dregs of a decoction, obtain alcohol extract;
5), to described alcohol extract carry out reduced pressure concentration and obtain corresponding thick medicinal extract, and reclaim ethanol;
6), to described thick medicinal extract carry out drying, obtain dry extract;
7), by described dry extract pulverize and sieve, obtaining extract extract powder;
8), prepare red colouring agent for food, also used as a Chinese medicine 85-170 part, and radiation sterilizing is carried out to prepared red colouring agent for food, also used as a Chinese medicine;
9), by the red colouring agent for food, also used as a Chinese medicine through sterilization processing pulverize, obtain red colouring agent for food, also used as a Chinese medicine powder;
10), by described red colouring agent for food, also used as a Chinese medicine powder mix with described extract extract powder, obtain the medicinal powder of described health product;
11), quantitative separating is carried out to described medicinal powder.
2. the preparation technology of the health products of reduction blood fat according to claim 1, is characterized in that, described preparation technology is also included in described dry extract and adds starch 8-25 part and dolomol 1.8-3.5 part.
3. the preparation technology of the health products of reduction blood fat according to claim 1, is characterized in that, the consumption of described red colouring agent for food, also used as a Chinese medicine is 135 parts, pseudo-ginseng 250 parts, Folium Apocyni Veneti 200 parts, ginkgo leaf 750 parts, the root of kudzu vine 750 parts.
4. the preparation technology of the health products of reduction blood fat according to claim 1, is characterized in that, described red colouring agent for food, also used as a Chinese medicine warp
60co radiation sterilizing, and when carrying out concentrated to alcohol extract, the concentrated condition adopted is: temperature 55 ~ 65 DEG C, vacuum 0.08MPa; And described alcohol extract being concentrated into relative density is 1.20 ~ 1.25.
5. the preparation technology of the health products of reduction blood fat according to claim 1, is characterized in that, described mixture is enclosed in capsule by described also comprising, and every capsules adds medicinal powder described in 0.4-0.5g.
6. one kind is reduced the health products of blood fat, it is characterized in that, pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part is comprised in described health products, or the extract of pseudo-ginseng 150-320 part, Folium Apocyni Veneti 130-270 part, ginkgo leaf 600-850 part, root of kudzu vine 650-900 part, and in described health products, comprise red colouring agent for food, also used as a Chinese medicine 85-170 part.
7. the health products of reduction blood fat according to claim 6, is characterized in that, described health products comprise pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, formed the after drying powder of dry extract of alcohol extract of the root of kudzu vine and the powder of red colouring agent for food, also used as a Chinese medicine.
8. the health products of reduction blood fat according to claim 6, is characterized in that, the consumption of each raw material is 135 parts, red colouring agent for food, also used as a Chinese medicine, pseudo-ginseng 250 parts, Folium Apocyni Veneti 200 parts, ginkgo leaf 750 parts, the root of kudzu vine 750 parts by mass.
9. the health products of reduction blood fat according to claim 6, is characterized in that, also comprise the water extract powder of auricularia auriculajudae, longan and matrimony vine in described health products.
10. an application for the health products for reducing blood fat according to claim 6-9 any one, is characterized in that, described health products are applied to Cardiovarscular.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510063794.0A CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510063794.0A CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104585767A true CN104585767A (en) | 2015-05-06 |
| CN104585767B CN104585767B (en) | 2018-03-06 |
Family
ID=53112101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510063794.0A Active CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104585767B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113499414A (en) * | 2021-08-27 | 2021-10-15 | 威海德尚医中医药科技有限公司 | A Chinese medicinal composition for thrombolysis and preventing cardiovascular diseases, and its preparation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101624563A (en) * | 2009-07-28 | 2010-01-13 | 崔凤玉 | Preparation method of hypolipidemic health care vinegar |
| CN102973821A (en) * | 2012-08-21 | 2013-03-20 | 苏州谷力生物科技有限公司 | Composition having vascular headache improvement effect |
| CN103735603A (en) * | 2014-02-11 | 2014-04-23 | 武汉市元大生物科技有限公司 | Compound lipid-decreasing soft capsule and preparation method thereof |
| CN103829238A (en) * | 2014-02-17 | 2014-06-04 | 大连圣弘医药有限公司 | Blood lipid lowering health food and preparation method thereof |
| CN103828983A (en) * | 2014-02-23 | 2014-06-04 | 廖洋镱 | Health-care eucommia bark tea |
-
2015
- 2015-02-06 CN CN201510063794.0A patent/CN104585767B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101624563A (en) * | 2009-07-28 | 2010-01-13 | 崔凤玉 | Preparation method of hypolipidemic health care vinegar |
| CN102973821A (en) * | 2012-08-21 | 2013-03-20 | 苏州谷力生物科技有限公司 | Composition having vascular headache improvement effect |
| CN103735603A (en) * | 2014-02-11 | 2014-04-23 | 武汉市元大生物科技有限公司 | Compound lipid-decreasing soft capsule and preparation method thereof |
| CN103829238A (en) * | 2014-02-17 | 2014-06-04 | 大连圣弘医药有限公司 | Blood lipid lowering health food and preparation method thereof |
| CN103828983A (en) * | 2014-02-23 | 2014-06-04 | 廖洋镱 | Health-care eucommia bark tea |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113499414A (en) * | 2021-08-27 | 2021-10-15 | 威海德尚医中医药科技有限公司 | A Chinese medicinal composition for thrombolysis and preventing cardiovascular diseases, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104585767B (en) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159227B (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN103518799B (en) | A kind of celery honey health care cake and preparation method thereof | |
| CN101253903B (en) | Health food with fat-reducing function and its preparation | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN103989163B (en) | A kind of blood stasis body constitution health food and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN102697843B (en) | Health care product for cleaning colon and promoting defecation, and eliminating toxin and beautifying skin and preparation method of same | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN103535625A (en) | Food for regulating and controlling blood glucose and preparation method thereof | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN104922548A (en) | Chinese herbal preparation for treatment of ascariasis | |
| CN104906190A (en) | Antler powder wine and preparation method thereof | |
| CN104585767A (en) | Health product with function of reducing blood fat and preparation process of health product | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN104621469A (en) | Food with function of reducing blood pressure | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
| CN109731089A (en) | A kind of composition and its preparation method and application adjusting liver-stomach disharmony |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |